If you are:
Not Recommended: POTENTIAL FOR EMBRYO/FETAL DEVELOPMENTAL TOXICITY, INHIBITS FOLATE METABOLISM
Precaution: CAUTION IN INFANT WITH HYPERBILIRUBINEMIA; SHOULD NOT USE IN G6PD-DEF INFANT
No Known Risk: NO REPORTED ADVERSE EFFECTS ON 50 INFANTS.
An adult over 60:
management or monitoring precaution: Renal-Rare risk of hyperkalemia. May need to monitor potassium and renal function. Dose adjust for CrCL < 31 mL/minute.
management or monitoring precaution: Renal-Impairment increases risk of severe adverse reactions (e.g. thrombocytopenia, bone marrow suppression, hyperkalemia, severe skin reactions). Monitor serum potassium and for folate deficiency with underlying impairment. Hepatic-Decreased hepatic function of aging increases risks of severe adverse reactions.
Giving Septra tablet to a child under 12:
Contraindication: Possible bilirubin displacement with kernicterus. Exceptional use for PCP prophylaxis.